JP7640527B2 - Ｒｎａ誘導ヌクレアーゼ及びその活性断片及び変異体ならびに使用方法 - Google Patents

Ｒｎａ誘導ヌクレアーゼ及びその活性断片及び変異体ならびに使用方法 Download PDF

Info

Publication number
JP7640527B2
JP7640527B2 JP2022509175A JP2022509175A JP7640527B2 JP 7640527 B2 JP7640527 B2 JP 7640527B2 JP 2022509175 A JP2022509175 A JP 2022509175A JP 2022509175 A JP2022509175 A JP 2022509175A JP 7640527 B2 JP7640527 B2 JP 7640527B2
Authority
JP
Japan
Prior art keywords
sequence
rgn
polypeptide
rna
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022509175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545385A5 (enExample
JP2022545385A (ja
Inventor
ディー．ボーエン タイソン
ブライナー クローリー アレクサンドラ
ディー．エリック テッド
コイル マイケル
Original Assignee
ライフエディット セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライフエディット セラピューティクス，インコーポレイティド filed Critical ライフエディット セラピューティクス，インコーポレイティド
Publication of JP2022545385A publication Critical patent/JP2022545385A/ja
Publication of JP2022545385A5 publication Critical patent/JP2022545385A5/ja
Priority to JP2025025892A priority Critical patent/JP2025086912A/ja
Application granted granted Critical
Publication of JP7640527B2 publication Critical patent/JP7640527B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022509175A 2019-08-12 2020-08-11 Ｒｎａ誘導ヌクレアーゼ及びその活性断片及び変異体ならびに使用方法 Active JP7640527B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025025892A JP2025086912A (ja) 2019-08-12 2025-02-20 Ｒｎａ誘導ヌクレアーゼ及びその活性断片及び変異体ならびに使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962885483P 2019-08-12 2019-08-12
US62/885,483 2019-08-12
US201962901875P 2019-09-18 2019-09-18
US62/901,875 2019-09-18
US202063030088P 2020-05-26 2020-05-26
US63/030,088 2020-05-26
PCT/US2020/045759 WO2021030344A1 (en) 2019-08-12 2020-08-11 Rna-guided nucleases and active fragments and variants thereof and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025025892A Division JP2025086912A (ja) 2019-08-12 2025-02-20 Ｒｎａ誘導ヌクレアーゼ及びその活性断片及び変異体ならびに使用方法

Publications (3)

Publication Number Publication Date
JP2022545385A JP2022545385A (ja) 2022-10-27
JP2022545385A5 JP2022545385A5 (enExample) 2023-08-21
JP7640527B2 true JP7640527B2 (ja) 2025-03-05

Family

ID=72243198

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509175A Active JP7640527B2 (ja) 2019-08-12 2020-08-11 Ｒｎａ誘導ヌクレアーゼ及びその活性断片及び変異体ならびに使用方法
JP2025025892A Pending JP2025086912A (ja) 2019-08-12 2025-02-20 Ｒｎａ誘導ヌクレアーゼ及びその活性断片及び変異体ならびに使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025025892A Pending JP2025086912A (ja) 2019-08-12 2025-02-20 Ｒｎａ誘導ヌクレアーゼ及びその活性断片及び変異体ならびに使用方法

Country Status (12)

Country Link
US (1) US12680096B2 (enExample)
EP (1) EP4013864A1 (enExample)
JP (2) JP7640527B2 (enExample)
KR (1) KR20220062289A (enExample)
CN (2) CN118813654A (enExample)
AU (1) AU2020329912A1 (enExample)
BR (1) BR112022002695A2 (enExample)
CA (1) CA3147783A1 (enExample)
IL (1) IL290562A (enExample)
MX (1) MX2022001849A (enExample)
TW (1) TW202120688A (enExample)
WO (1) WO2021030344A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
CN113631704A (zh) * 2018-12-27 2021-11-09 生命编辑制药股份有限公司 可用于基因编辑的多肽及使用方法
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
JP2023516226A (ja) 2020-04-24 2023-04-18 ライフエディット セラピューティクス，インコーポレイティド Ｒｎａ誘導型ヌクレアーゼとその活性な断片およびバリアント、ならびに利用の方法
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN116194581A (zh) 2020-07-01 2023-05-30 艾勒维生技公司 使用环状rna进行细胞重编程的组合物和方法
JP7890972B2 (ja) 2020-07-15 2026-07-15 ライフ エディット セラピューティクス，インコーポレイティド ウラシル安定化タンパク質並びにその活性断片及びバリアント並びに使用方法
EP4211235A2 (en) 2020-09-11 2023-07-19 Lifeedit Therapeutics, Inc. Dna modifying enzymes and active fragments and variants thereof and methods of use
CA3173950A1 (en) * 2021-03-22 2022-09-22 Tyson D. BOWEN Dna modifyng enzymes and active fragments and variants thereof and methods of use
US20250011740A1 (en) * 2021-04-22 2025-01-09 Emendobio Inc. Novel omni 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 and 262 crispr nucleases
WO2024077267A1 (en) * 2022-10-07 2024-04-11 The Broad Institute, Inc. Prime editing methods and compositions for treating triplet repeat disorders
IL320573A (en) 2022-11-04 2025-07-01 Life Edit Therapeutics Inc Developed adenine deaminases and RNA-guided nuclease fusion proteins with internal insertion sites and methods of use
WO2024127370A1 (en) * 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target trac gene and methods of use
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
WO2025174908A1 (en) * 2024-02-12 2025-08-21 Life Edit Therapeutics, Inc. Novel rna-guided nucleases and proteins for polymerase editing
TW202617985A (zh) 2024-06-25 2026-05-01 美商生命編輯治療學公司 新穎反轉錄酶及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033298A1 (en) 2014-08-28 2016-03-03 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
WO2016186946A1 (en) 2015-05-15 2016-11-24 Pioneer Hi-Bred International, Inc. Rapid characterization of cas endonuclease systems, pam sequences and guide rna elements
WO2017155714A1 (en) 2016-03-11 2017-09-14 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
WO2017155717A1 (en) 2016-03-11 2017-09-14 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
WO2018172556A1 (en) 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
WO2019036185A1 (en) 2017-08-15 2019-02-21 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR IMPROVING GENOMIC SEQUENCE CORRECTION
JP2019520079A (ja) 2016-07-06 2019-07-18 クリスパー セラピューティクス アクチェンゲゼルシャフト 疼痛関連障害を処置するための物質及び方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5569597A (en) 1985-05-13 1996-10-29 Ciba Geigy Corp. Methods of inserting viral DNA into plant material
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4853331A (en) 1985-08-16 1989-08-01 Mycogen Corporation Cloning and expression of Bacillus thuringiensis toxin gene toxic to beetles of the order Coleoptera
US5268463A (en) 1986-11-11 1993-12-07 Jefferson Richard A Plant promoter α-glucuronidase gene construct
US5608142A (en) 1986-12-03 1997-03-04 Agracetus, Inc. Insecticidal cotton plants
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5039523A (en) 1988-10-27 1991-08-13 Mycogen Corporation Novel Bacillus thuringiensis isolate denoted B.t. PS81F, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin
KR920701453A (ko) 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
ES2187497T3 (es) 1990-04-12 2003-06-16 Syngenta Participations Ag Promotores preferentemente en tejidos.
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5498830A (en) 1990-06-18 1996-03-12 Monsanto Company Decreased oil content in plant seeds
CA2051562C (en) 1990-10-12 2003-12-02 Jewel M. Payne Bacillus thuringiensis isolates active against dipteran pests
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5399680A (en) 1991-05-22 1995-03-21 The Salk Institute For Biological Studies Rice chitinase promoter
JPH06510187A (ja) 1991-08-27 1994-11-17 ノバルティス　アクチエンゲゼルシャフト 同翅類昆虫に対する殺虫性質を有したタンパク質及び植物保護におけるそれらの用法
TW261517B (enExample) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5789156A (en) 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5608144A (en) 1994-08-12 1997-03-04 Dna Plant Technology Corp. Plant group 2 promoters and uses thereof
US5659026A (en) 1995-03-24 1997-08-19 Pioneer Hi-Bred International ALS3 promoter
US6072050A (en) 1996-06-11 2000-06-06 Pioneer Hi-Bred International, Inc. Synthetic promoters
ES2270227T3 (es) 1998-02-26 2007-04-01 Pioneer Hi-Bred International, Inc. Promotor met-1 del maiz.
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
CN1360632A (zh) 1999-05-04 2002-07-24 孟山都技术有限公司 鞘翅目毒性多肽组合物和抗虫转基因植物
BR0014516A (pt) 1999-09-15 2002-07-02 Monsanto Technology Llc Composições e métodos de uso de delta-endotoxina do bacilo thuringiensis ativo de lepidopteran
US20050183161A1 (en) 2003-10-14 2005-08-18 Athenix Corporation AXMI-010, a delta-endotoxin gene and methods for its use
US7629504B2 (en) 2003-12-22 2009-12-08 Pioneer Hi-Bred International, Inc. Bacillus thuringiensis cry9 nucleic acids
ES2397118T3 (es) 2006-06-14 2013-03-04 Athenix Corporation AXMI-031, AXMI-039 ,AXMI-040 y AXMI-049, una familia de genes de endotoxina delta y métodos para su uso
ES2738980T3 (es) 2008-09-15 2020-01-28 Childrens Medical Ct Corp Modulación de BCL11A para el tratamiento de hemoglobinopatías
CN102648281B (zh) 2009-07-02 2017-04-05 阿森尼克斯公司 Axmi‑205杀虫基因和它的使用方法
US8586832B2 (en) 2009-12-21 2013-11-19 Pioneer Hi Bred International Inc Bacillus thuringiensis gene with Lepidopteran activity
KR101445945B1 (ko) 2009-12-24 2014-09-29 제이엑스 닛코 닛세키 킨조쿠 가부시키가이샤 가돌리늄제 스퍼터링 타깃 및 동 타깃의 제조 방법
CN103154247A (zh) 2010-08-19 2013-06-12 先锋国际良种公司 对鳞翅目昆虫具有活性的新苏云金杆菌基因
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
HUE051612T2 (hu) 2012-07-11 2021-03-01 Sangamo Therapeutics Inc Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
ES2749624T3 (es) 2013-03-14 2020-03-23 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
SG11201510327TA (en) 2013-06-17 2016-01-28 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
CN105517579B (zh) 2013-07-10 2019-11-15 哈佛大学校长及研究员协会 用于RNA向导的基因调节和编辑的正交Cas9蛋白
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
US11208638B2 (en) 2015-01-12 2021-12-28 The Regents Of The University Of California Heterodimeric Cas9 and methods of use thereof
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CN116555254A (zh) 2015-10-09 2023-08-08 孟山都技术公司 新颖的rna导向性核酸酶及其用途
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
CA3029119A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
CA3029121A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2018002762A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
CA3029130A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of apolipoprotein c3 (apociii)-related disorders
WO2018002886A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia 3 (sca3) and other related disorders
EP4650364A3 (en) 2016-07-06 2026-01-21 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11180778B2 (en) 2016-11-11 2021-11-23 The Regents Of The University Of California Variant RNA-guided polypeptides and methods of use
EA201990815A1 (ru) 2016-11-14 2019-09-30 Институте Оф Генетисс Анд Девелопментал Биологй. Чинесе Асадемй Оф Ссиенсес Способ редактирования основания у растений
WO2018154462A2 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585896A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of merosin-deficient cogenital muscular dystrophy (mdcmd) and other laminin, alpha 2 (lama2) gene related conditions or disorders
AU2018224387B2 (en) 2017-02-22 2024-08-08 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2018154439A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
WO2018154418A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
EP3585899A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
WO2018154413A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders
JP7277052B2 (ja) 2017-02-22 2023-05-18 クリスパー セラピューティクス アーゲー プロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）関連障害の処置のための組成物および方法
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
BR112019023377A2 (pt) 2017-05-11 2020-06-16 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Criação de um gene resistente a herbicida e uso do mesmo
CA3063733A1 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Base editors with improved precision and specificity
WO2019051097A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of California RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME
EP3714055A1 (en) 2017-11-21 2020-09-30 CRISPR Therapeutics AG Materials and methods for treatment of autosomal dominant retinitis pigmentosa
JP2021505159A (ja) 2017-12-06 2021-02-18 ジェネレーション バイオ カンパニー 修飾型閉端ｄｎａ（ｃｅｄｎａ）を使用する遺伝子編集
KR20200124702A (ko) 2018-02-23 2020-11-03 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 신규한 cas9 오르소로그
JP7550648B2 (ja) 2018-03-19 2024-09-13 クリスパー セラピューティクス アーゲー 新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
AU2019282149B2 (en) 2018-06-05 2025-08-21 Life Edit Therapeutics, Inc. RNA-guided nucleases and active fragments and variants thereof and methods of use
US12540352B2 (en) * 2018-09-20 2026-02-03 Institute Of Zoology, Chinese Academy Of Sciences Method for detecting nucleic acid
CA3121191A1 (en) 2018-11-28 2020-06-04 Crispr Therapeutics Ag Optimized mrna encoding cas9 for use in lnps
CA3125175A1 (en) 2018-12-27 2020-07-02 LifeEDIT Therapeutics, Inc. Polypeptides useful for gene editing and methods of use
CN113631704A (zh) 2018-12-27 2021-11-09 生命编辑制药股份有限公司 可用于基因编辑的多肽及使用方法
US20220145274A1 (en) 2019-03-12 2022-05-12 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
US12173290B2 (en) 2019-06-28 2024-12-24 Crispr Therapeutics Ag Materials and methods for controlling gene editing

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033298A1 (en) 2014-08-28 2016-03-03 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
WO2016186946A1 (en) 2015-05-15 2016-11-24 Pioneer Hi-Bred International, Inc. Rapid characterization of cas endonuclease systems, pam sequences and guide rna elements
WO2017155714A1 (en) 2016-03-11 2017-09-14 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
WO2017155717A1 (en) 2016-03-11 2017-09-14 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
JP2019520079A (ja) 2016-07-06 2019-07-18 クリスパー セラピューティクス アクチェンゲゼルシャフト 疼痛関連障害を処置するための物質及び方法
WO2018172556A1 (en) 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
WO2019036185A1 (en) 2017-08-15 2019-02-21 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR IMPROVING GENOMIC SEQUENCE CORRECTION

Also Published As

Publication number Publication date
KR20220062289A (ko) 2022-05-16
BR112022002695A2 (pt) 2022-08-23
AU2020329912A1 (en) 2022-03-24
CA3147783A1 (en) 2021-02-18
EP4013864A1 (en) 2022-06-22
CN114641568A (zh) 2022-06-17
CN118813654A (zh) 2024-10-22
MX2022001849A (es) 2022-03-11
US12680096B2 (en) 2026-07-14
TW202120688A (zh) 2021-06-01
WO2021030344A1 (en) 2021-02-18
JP2022545385A (ja) 2022-10-27
US20220364074A1 (en) 2022-11-17
IL290562A (en) 2022-04-01
JP2025086912A (ja) 2025-06-09
CN114641568B (zh) 2024-09-06

Similar Documents

Publication Publication Date Title
US12338455B2 (en) RNA-guided nucleases and active fragments and variants thereof and methods of use
US12188018B2 (en) Polypeptides useful for gene editing and methods of use
JP2025086912A (ja) Ｒｎａ誘導ヌクレアーゼ及びその活性断片及び変異体ならびに使用方法
CN116096879A (zh) Rna引导的核酸酶及其活性片段和变体以及使用方法
EA049684B1 (ru) Рнк-направляемые нуклеазы, их активные фрагменты и варианты, а также способы применения
EA047491B1 (ru) Рнк-направляемые нуклеазы, их активные фрагменты и варианты, а также способы применения
HK40050306B (en) Rna-guided nucleases and active fragments and variants thereof and methods of use
HK40050306A (en) Rna-guided nucleases and active fragments and variants thereof and methods of use
EA046542B1 (ru) Рнк-управляемые нуклеазы и активные фрагменты, и их варианты и способы применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250220

R150 Certificate of patent or registration of utility model

Ref document number: 7640527

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150